Itrakonazol Actavis

Itraconazole, the active ingredient in Itrakonazol Actavis, is a azole antifungal presented as an oral formulation for systemic use. It treats a range of deep‑tissue and cutaneous fungal infections in adult patients.

GNH USA supplies Itrakonazol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itrakonazol Actavis is an azole antifungal used to manage systemic and localized fungal infections. - Aspergillosis: eradicates invasive Aspergillus species and prevents disease progression. - Blastomycosis: clears Blastomyces dermatitidis infection in pulmonary and disseminated forms. - Histoplasmosis: resolves Histoplasma capsulatum infection, especially in immunocompromised hosts. - Coccidioidomycosis: treats Coccidioides immitis/posadasii infections of the lungs and other sites. - Dermatophytosis: eliminates skin‑surface dermatophyte infections resistant to other agents. - Onychomycosis: improves nail‑plate involvement caused by dermatophytes and yeasts.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the abdomen. - Diarrhea: loose stools occurring intermittently. - Rash: mild skin irritation or erythema. - Elevated liver enzymes: mild increases in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Congestive heart failure: fluid retention and reduced cardiac output. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - QT prolongation: potential cardiac arrhythmias. - Visual disturbances: blurred vision or photopsia. - Hepatic failure: rare but life‑threatening liver dysfunction.

Itrakonazol Actavis requires careful monitoring and patient assessment before and during therapy. - Liver function monitoring: check transaminases before initiation and periodically thereafter. - Cardiac assessment: evaluate for heart failure history prior to use. - Drug interaction review: assess concomitant CYP3A4 substrates and inhibitors. - Renal impairment caution: adjust therapy in severe kidney disease. - Hypersensitivity avoidance: discontinue if allergic reactions occur. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Itrakonazol Actavis can alter the plasma concentrations of several co‑administered drugs. Major Interactions (Avoid): - Simvastatin and other strong CYP3A4 substrates: risk of severe myopathy. - Rifampin: potent inducer that reduces itraconazole exposure. - Ketoconazole: additive CYP3A4 inhibition leading to toxicity. Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect, monitor INR. - Oral contraceptives: efficacy may be reduced, advise backup method. - Digoxin: possible increase in serum levels, observe for toxicity.